Back to Browse Journals » Journal of Blood Medicine » Volume 3

Newer agents in antiplatelet therapy: a review

Authors Yeung J, Holinstat M

Published Date June 2012 Volume 2012:3 Pages 33—42

DOI http://dx.doi.org/10.2147/JBM.S25421

Received 1 May 2012, Accepted 17 May 2012, Published 25 June 2012

Jennifer Yeung, Michael Holinstat

Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA

Abstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although there has been significant advancement in antiplatelet therapeutic approaches, aspirin still remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies. The pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number of antiplatelet inhibitors currently in use due to variability in metabolism, time to onset, and reversibility. A focused effort in the development of newer antiplatelet therapies to address some of these shortcomings has resulted in a significant number of potential antiplatelet drugs which target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, prostaglandins, protease-activated receptors, thromboxane), and glycoproteins (αIIbß3, GPVI, vWF, GPIb) in the platelet. The validation and search for newer antiplatelet therapeutic approaches proven to be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with fewer untoward side-effects to what is currently in use today.

Keywords: platelet aggregation inhibitors, blood platelets, purinergic P2Y receptor antagonists, receptor, PAR-1, platelet glycoprotein GPIIb-IIIa, thrombosis

Erratum for this paper has been published.

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Erratum

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:49-50

Published Date: 3 August 2012

Readers of this article also read:

Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation

Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K

Journal of Blood Medicine 2012, 3:157-161

Published Date: 5 December 2012

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

Piccaluga PP, Paolini S, Bertuzzi C, De Leo A, Rosti G

Journal of Blood Medicine 2012, 3:151-156

Published Date: 29 November 2012

Optimal management of pernicious anemia

Andres E, Serraj K

Journal of Blood Medicine 2012, 3:97-103

Published Date: 10 September 2012

Erratum

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:49-50

Published Date: 3 August 2012

Deep vein thrombosis: a clinical review

Kesieme EB, Kesieme CN, Jebbin N, Irekpita E, Dongo A

Journal of Blood Medicine 2011, 2:59-69

Published Date: 29 April 2011

The western diet and lifestyle and diseases of civilization

Pedro Carrera-Bastos, Maelan Fontes-Villalba, James H O’Keefe, et al

Research Reports in Clinical Cardiology 2011, 2:15-35

Published Date: 9 March 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009